Sign In
Buy VTGN
$0.560
-0.0199 (-3.43%)
At Close: Jun 03, 2026
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm
03:00pm, Monday, 01'st Jun 2026
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, June 1,
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm
02:40pm, Monday, 01'st Jun 2026
NEW YORK, June 1, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) breache
Vistagen to Participate in Jefferies 2026 Global Healthcare Conference
08:30am, Wednesday, 27'th May 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen to Participate in Jefferies 2026 Global Healthcare Conference.
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer
08:30am, Tuesday, 19'th May 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci
Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
08:30am, Thursday, 14'th May 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen, a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new cla
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm
03:12pm, Wednesday, 29'th Apr 2026
NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) b
SAN FRANCISCO, April 28, 2026 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises Vistagen Therapeutics, Inc. (NASDAQ: VTGN) investors that the firm is investigating potential legal claims arising
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm
10:13am, Monday, 20'th Apr 2026
New York, New York--(Newsfile Corp. - April 20, 2026) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vistagen Therapeutics, Inc . (NAS
VistaGen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Below Fifty Day Moving Average – Should You Sell?
04:10am, Saturday, 11'th Apr 2026
VistaGen Therapeutics, Inc. (NASDAQ: VTGN - Get Free Report) crossed below its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $0.58 and traded as low as $0.55
VistaGen Therapeutics (NASDAQ:VTGN) Stock Passes Above 50-Day Moving Average – Here’s Why
04:12am, Friday, 20'th Mar 2026
Shares of VistaGen Therapeutics, Inc. (NASDAQ: VTGN - Get Free Report) passed above its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $0.60 and traded as h
NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Vistagen Therapeutics, Inc. (“Vistagen” or the “Company”) (NASDAQ: VTGN)
NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Vistagen Therapeutics, Inc. (“Vistagen” or the “Company”) (NASDAQ: VTGN)
